docPediatric Vaccines Market Size, Analysis, and Forecast Report: 2016-2026
download 
Report Transcription
Pediatric Vaccines Market Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2016 Future Market Insights www.futuremarketinsights.com sales@futuremarketinsights.com Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client. Research Capabilities Sector Coverage Customized Research Syndicated Research Investment Research Social Media Research Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment Customized Research Subscription Information Syndicated Research For detailed subscription information please contact Investment Research T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Social Media Research Hari. T (Sr. Manager - Global Business Development) Email: hari.t@futuremarketinsights.com Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas Report Description Report Description Vaccination is a technique by which person is made immune or resistant to an infectious disease. Vaccination has saved millions of lives including adults, children, and animals, providing them a better quality and healthier life from various microorganism such as virus and bacteria. This is one of the most important reason behind the growth of this market. Vaccines stimulate the body's own immune system to protect the person against subsequent infection or disease. Vaccines are generally segmented into two target markets, adult and pediatric. Pediatric vaccines are commonly used for the immunization of children and adolescents against various various infectious diseases, like diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. Pediatric Vaccines Market: Drivers and Restrains Major growth drivers for the growth of global pediatric vaccines market are increasing private-public partnerships for the research and development activities, technological advancement in recombinant DNA technology, increasing healthcare expenditure. Both government and non-government bodies are focusing a lot on immunization campaigns to increase awareness about vaccination among population. However, rising costs of vaccines, low accessibility to remote areas and stringent regulation for approval of vaccines are some of the factors affecting the global pediatric vaccine. Request free sample Report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1317 Report Description Report Description Pediatric Vaccines Market: Segmentation The global pediatric vaccines market can be segmented based on products, technology and types of diseases. Based on vaccines type, global pediatric vaccine market can be segmented into following: • Live, attenuated vaccines, • Inactivated/killed vaccines, • Toxoid vaccines • Subunit/Conjugate • Recombinant vector vaccines Based on diseases type, global pediatric vaccine can be segmented into following: • Diphtheria • Hepatitis A • Hepatitis B • Influenza • Measles Report Description Report Description • Meningococcal • Mumps • Haemophilus Influenzae type b (Hib) • Pertussis • Pneumococcal disease • Polio • Rotavirus(severe diarrhea) • Rubella(German measles) • Tetanus(lockjaw) • Varicella(chickenpox) Pediatric Vaccines Market: Overview The pediatric vaccines market has reported a favorable growth due to increasing rate of birth around the world. The continuous occurrence of infectious diseases has created a high demand for pediatric vaccines market. Among all segments, the market of live, attenuated vaccines based on technology has reported a highest demand. By disease type, infectious diseases segment is one the segment of fastest growth in global pediatric market, in upcoming years. Report Description Report Description Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1317 Pediatric Vaccines Market: Regional Overview Depending on geographic regions, global hypercalcemia market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa. Geographically, North America is leading the global pediatric vaccines market because of high awareness among population for childhood vaccination. Asia Pacific is also one of the fasted growing region in global pediatric vaccines market due to high involvement of government-non-government bodies in promoting vaccination campaigns, and making available some of life saving pediatric vaccines on regular basis at free of cost. European market is about to grow due to increasing focus on technology innovation, translation research and development of pediatric vaccines, and expanding global co-operation among nations. Pediatric Vaccines Market: Key Player Some of the major players operating in global pediatric vaccines market are Novartis, Medimmune, Pfizer, Sanofi, Merck, GlaxoSmithKline, Emergent Bio solutions, Bharat Biotech, Baxter International, Bavarian Nordic and AlphaVax. Browse full report: http://www.futuremarketinsights.com/reports/pediatric-vaccinesmarket Thank You! To know more about us, please visit our website: www.futuremarketinsights.com For sales queries or new topics email us on: sales@futuremarketinsights.com For other queries contact: Mr. Sudip Saha Future Market Insights: 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 | D: +1-845-579-5705
Similar documents
Now Available: Meningococcal Vaccines Market Forecast and Growth 2016-2026
Meningococcal disease is a potentially fatal illness caused due to bacterium known as Neisseria meningitides. The bacteria is known to cause serious infection in the meninges, which are thin layers of connective tissues surrounding the brain and spinal cord. Common clinical symptoms of meningococcal disease are meningitis, bacteremia, and pneumonia. Other less common indications include myocarditis, endocarditis or pericarditis, arthritis, conjunctivitis, urethritis, pharyngitis, and cervicitis. Symptoms associated with these disease include high fever, neck stiffness, confusion, nausea, vomiting, lethargy, and petechial rashes.
Meningococcal vaccines are known to be found on the World Health Organization’s List of Essential Medicines. The bacteria can be classified into over 10 serotypes based in their immunologic reactivity. Currently, globally marketed meningococcal vaccines are of four types - polysaccharide-based, bivalent (Serogroup A and C), trivalent (Serogroup A, C and W-135), and tetravalent (Serogroup A, C, Y and W-135). There is currently only one vaccine available for Serogroup B in the US, while it account for over one-third of the disease cases in the country. The nature and components of the vaccines are purified, heat-stable, lyophilized capsular polysaccharides derived from the meningococci of the respective serogroups.
Request free sample Report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1252
Disease epidemiology of the meningococcal disease has undergone a radical change over the last century. Case-fatality ratios have witnessed a decline of from a high of 70% in the first part of the twentieth century to less than 15% after 2000. Of late the disease caused by Serogroup Y has increased from prevalence rate of 2% to over 35% between 1990 and 2005. The disease is contractible in nature primarily through antimicrobial chemoprophylaxis. There are currently three meningococcal vaccines available in the US to prevent this life-threatening disease. However, these vaccines frequently feature under the list of critical drugs in shortage.
Meningococcal Vaccines Market: Drivers and Restraints
The primary driver of meningococcal vaccines are introduction of advanced serotype B vaccines from large global drugmakers such as Novartis and Pfizer. The expansion of routine immunization programs across all parts of the world is much needed for the commercial success of these vaccines. Increase in funding from the government of compulsory immunizations at birth will also reduce out-of-pocket expenses of patients and increase affordable access to meningitis vaccines. Further, higher annual meningococcal disease incidence among infants and healthy young adults also is likely to encourage use of the vaccine.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1252
The prime barriers of the market include price wars for the vaccines from comparable drugmakers that may wipe out a greater customer base and reduce overall customer coverage. The other barrier includes increasing financial austerity in the European nations, which is expected to hamper the R&D base for the vaccines. Further, serotype mismatch and less than optimum coverage across countries is likely to negatively affect the demand for the vaccines. A delay in assessing the disease epidemiology over regular intervals due to cost issues may negatively impact the market for meningococcal vaccines over the long-term in the developing nations.
Meningococcal Vaccines Market: Segmentation
Global Compression Therapy Devices is further segmented into these following types:
By Product Type
• Monovalent
• Bivalent
• Trivalent
• Tetravalent or Quadrivalent
By formulation
• Polysaccharide-based
• Conjugate-based
• Combination-based
By indication
• Pneumonia
• Meningitis
• Bacteremia
• Others (arthritis, conjunctivitis, Urethritis)
Meningococcal Vaccines Market: Overview
With the advancement of research and development, increase in awareness of disease incidence and increasing government support in routine immunizations the meningococcal vaccines Market is gaining traction as a treatment of choice among patients. This market is expected to grow at a healthy CAGR in the forecast period (2015-2025).
Browse full report: http://www.futuremarketinsights.com/reports/meningococcal-vaccines-market
Rising prophylactic vaccination among infants, who tend to cover the largest endemic population are expected to drive the market in the forecast period.
Meningococcal Vaccines Market: Region-wise Outlook
Depending on geographic regions, global compression therapy market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.
In terms of geography, North America dominates the Meningococcal Vaccines Market market, followed by Europe. Growing aging population and increasing prevalence of diabetes are also supporting the growth of compression therapy market in this regions. India, China, and Japan are expected to be the fastest-growing markets for compression therapy in Asia.
Meningococcal Vaccines Market: Key Players
Some of the key players in compression therapy market are GlaxoSmithKline PLC, JN-International Medical Corporation, Novartis International AG, Sanofi SA, Pfizer, Inc. and Baxter International, Inc
Global Anti-Infective Vaccines Market
Rapidly spreading infectious diseases such as tuberculosis, malaria, Hepatitis B, HIV/AIDS, influenza and others are becoming major concern to the society and the healthcare professionals as they are majorly contributing to worldwide causes of death and presenting huge burden on healthcare systems. Infectious diseases are treated with category of drugs including antivirals and anti-infective agents along with adjunct therapy of immune system boosters.